Although chemotherapy as a single modality has demonstrated limited efficacy, it may improve the result as a concurrent treatment [11].
Data demonstrate limited efficacy and partially deleterious adverse-effect profiles for conventional antiarrhythmic agents for AF.
The current treatment options demonstrate limited efficacy and severe side-effects.
Similarly, orthodox systemic chemotherapeutic (SC) strategies for CPM have demonstrated limited efficacy, at least in part owing to the plasma peritoneal barrier that significantly restricts intraperitoneal drug localisation.
In this setting, clinical studies of endocrine monotherapy or combinations of endocrine agents have demonstrated limited efficacy [ 8, 20], and the optimal sequence of endocrine treatment remains unclear.
Recent reports have described the use of various therapies for refractory cGVHD, but the results have demonstrated limited efficacy and low long-term survival due to toxicity.
Trials have begun to evaluate the anti-BAFF agent belimumab (LymphoStat-B; Human Genome Sciences, Rockville, MD, USA) in RA and have demonstrated limited efficacy, perhaps because of incomplete blockade or because other related B-cell survival factors such as a proliferation-inducing ligand (APRIL) would not be affected.
Existing drug treatments show limited efficacy in malaria elimination [ 2- 6].
However, most MEK inhibitors have demonstrated limited clinical efficacy as single-agent therapies [3, 4].
Consequently, drugs targeting mitosis demonstrate limited clinical efficacy, which exposes a fundamental weakness in the rationale underlying their clinical development.
Multiple studies demonstrated a limited efficacy of standard atropine oxime treatment in nerve agent poisoning and called for the development of alternative and more effective treatment strategies.
